Zydus Settles Mirabegron Patent Dispute With Astellas for USD 120 Million

Published On 2026-02-13 10:01 GMT | Update On 2026-02-13 10:01 GMT

New Delhi: Zydus Lifesciences has entered into a settlement agreement with Astellas Pharma Inc. to resolve ongoing patent litigation in the United States related to Myrbetriq (Mirabegron).

The company informed the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that it, along with its wholly owned subsidiary Zydus Pharmaceuticals USA, Inc., has executed a Settlement Agreement with Astellas.

The development follows Zydus’ earlier disclosure dated April 17, 2025, regarding US patent litigation concerning Astellas’ Myrbetriq (generic name: Mirabegron).

Under the terms of the agreement, Zydus will pay Astellas an aggregate amount of USD 120 million. In addition, the company will pay a prepaid per-unit licensing fee on units of its generic Mirabegron sold in the US from the date of the Settlement Agreement through September 2027.

Also Read: USFDA Grants Orphan Drug Status to Zydus' Desidustat for Sickle Cell Disease

Other terms of the agreement remain confidential.

The settlement concludes all pending litigations between Astellas and Zydus relating to Myrbetriq and Mirabegron. Importantly, the agreement enables Zydus to continue marketing its generic Mirabegron in the United States.

Mirabegron is indicated for the treatment of overactive bladder and represents a significant product in the US urology segment. The resolution removes legal uncertainty around Zydus’ ability to continue selling the product in the highly competitive US generics market.

Also Read: UP Pharma Conclave 1.0: CM Yogi Promises Safety, Stability, Speed to Global Pharma Investors

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

sheeba farhat

Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus Settles Mirabegron Patent Dispute With Astellas for USD 120 Million

Similar News

Lupin Appoints Dr Kushkumar Thakare as Manager, Medical Affairs for India Region

USFDA Concludes PAI at Cipla Subsidiary InvaGen With 2 Observations

Akums Secures First UK MHRA Approval for Rivaroxaban

Indian Pharma Market Kicks Off 2026 With 10% Growth in January: PharmaTrac

USFDA Issues 9 Observations to Aurobindo's Jedcherla Unit-VII After Inspection

GST Probe at Mankind Pharma's BSV Unit in Mumbai

OneSource Secures Saudi Nod for Generic Ozempic, Partners Hikma for MENA Rollout